{Reference Type}: Journal Article
{Title}: Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps.
{Author}: Li X;Li J;Xu X;She W;Wang C;Zhang Y;Zhang L;
{Journal}: Expert Rev Clin Immunol
{Volume}: 19
{Issue}: 11
{Year}: 2023 Jul-Dec 13
{Factor}: 5.124
{DOI}: 10.1080/1744666X.2023.2246660
{Abstract}: <B>UNASSIGNED: </B>Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a common and challenging clinical entity, and its economic burden has not been well described in China thus far.<BR><B>UNASSIGNED: </B>A total of 101 CRSwNP patients who underwent endoscopic sinus surgery were included to investigate direct costs in the first year post-surgery. Costs for outpatient visits, medication use, and examination costs were obtained from the Hospital Information System, and differences were compared between subgroups. Multiple linear regression analysis was adopted to investigate the main influencing factors on annual total direct costs for CRSwNP patients.<BR><B>UNASSIGNED: </B>Ninety-two subjects completed the study. The individual mean total direct cost for a CRSwNP patient 1 year post-surgery was $742.4. The largest contributors were pharmacy costs ($580.2), followed by examination costs ($108.1) and outpatient visits ($54.1). Total direct costs were higher in subgroups of patients with uncontrolled clinical status, asthma comorbidity, and eosinophilic CRSwNP compared to their counterparts. The main influencing factors were clinical control status (P = 0.016) and asthma comorbidity (P = 0.035).<BR><B>UNASSIGNED: </B>The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.